MEGACE
MEGESTROL ACETATE
Approval overview MEGACE is listed in Drugs@FDA under application 020264 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient MEGESTROL ACETATE Form and strength SUSPENSION;ORAL - 40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor BRISTOL MYERS SQUIBB Submission history Latest submission status date: 2019-07-18 00:00:00.
Structured Monograph
Clinical summary
Approval overview MEGACE is listed in Drugs@FDA under application 020264 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient MEGESTROL ACETATE Form and strength SUSPENSION;ORAL - 40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor BRISTOL MYERS SQUIBB Submission history Latest submission status date: 2019-07-18 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.